GNW-Adhoc: ONWARD strengthens management team in key positions in the areas of Clinical & Regulatory and Marketing

^EINDHOVEN, Netherlands, LAUSANNE, Switzerland and BOSTON, MA, Nov. 06, 2023 (GLOBE

NEWSWIRE) — The medical technology company ONWARD Medical NV (Euronext: ONWD),

the innovative therapies to restore movement, independence and

Health for people with spinal cord injuries (SCI)

developed, announced today the appointment of two key members of its

Leadership teams known to clinical research and commercial

to advance the company’s activities. Both new additions will be in the USA

and report to Dave Marver, CEO.

New VP Global Clinical & Regulatory – Erika Ross, PhD

Dr. Erika Ross will join ONWARD as Vice President, effective January 23, 2023,

Global Clinical & Regulatory. In this newly created position

She will lead global clinical and regulatory activities

from ONWARD.

Before working at ONWARD, Dr. Erika Ross as Director, Global Clinical

& Applied Research at Abbott Neuromodulation. She previously headed as

Neuroscience Director at Cala Health the scientific research program,

that for the De Novo approval and introduction of the neurostimulation technology of the

company led. Miss Dr. Ross was also at the Mayo Clinic as

Deputy Director of the Medical Device Innovation Accelerator

Department of Surgery and as an assistant professor in the Department of

neurological surgery. She holds a B.Sc. in

Biology and Economics as well as an M.Sc. in molecular biology from the

University of Denver and received his doctorate in neuroscience from the Mayo Clinic.

“I’m pleased, Dr. Welcoming Erika Ross to our leadership team,”

said Dave Marver, Chief Executive Officer.?Their extensive expertise in

The field of neuromodulation will help our company prepare for the

Commercialization of the numerous promising therapies in our pipeline

strengthen. Erika also brings excellent relationships with researchers and

Clinicians with whom they met during their work in neuroscience and the

Neurosurgery at the Mayo Clinic and after moving to the

industry has maintained.”

“I feel honored to be involved in the further development of ONWARD’s therapies

to be able to help meet the great unmet needs of people

to cover spinal cord injuries. I’m also very happy to be part of this

committed and extremely capable leadership teams committed to this

is committed to making these important therapies accessible as quickly as possible

do,” commented Dr. Erika Ross.

New VP, Global Marketing – Sarah Moore

Sarah Moore will become Vice President, Global, effective February 1, 2023

Marketing by ONWARD. In this role she will be responsible for the worldwide

ONWARD’s marketing activities, including:

Product management and market launch planning.

Sarah Moore previously worked as Head of Commercial Marketing at Nevro, a

Implantable neuromodulation company. Before that she had different ones

Leading positions in global marketing for several medical technology companies

at Johnson & Johnson, most recently as head of Advanced Imaging

business unit of J&J. Ms. Moore holds an MBA from the

Duke University and a BA in German from Washington and Lee University.

?Sarah Moore’s extensive experience in medical device marketing

and especially neuromodulation therapies will be invaluable to us

be as we prepare to receive our first therapy later this year

to the market this year,” said Dave Marver.?It brings a variety of

Skills that go far beyond marketing and help us

Scaling will help.”

“I am fascinated by ONWARD’s mission and it is an honor to do so

to complement a first-class team dedicated to restoring

physical functions in people with spinal cord injuries.

I look forward to working with the medical community to address this

bringing groundbreaking therapy to market,” added Sarah Moore.

About ONWARD Medical

ONWARD is a medical technology company that provides innovative therapies

Restoring movement, independence and health in people with

Spinal cord injuries developed. ONWARD’s work is based on more than

a decade of basic research and preclinical development in

carried out in the world’s leading neuroscience laboratories. The ARC

Therapy of ONWARD using implantable (ARC-IM) or external (ARC-EX)

Systems can be carried out, serves the targeted, programmed

Stimulation of the spinal cord to enable movement and other functions in humans

with spinal cord injuries and thus improve their quality of life

improve.

ONWARD has five breakthrough device designations from the US FDA

that include both ARC-IM and ARC-EX. ARC-EX is an external,

non-invasive platform consisting of a wearable stimulator and a

wireless programming device. Positive topline results were reported in 2022

the company’s first pivotal study, Up-LIFT, was published in the

the ability of ARC-EX therapy to improve the strength and function of the

upper extremities was evaluated. The company is now preparing

Applications for approval for the USA and Europe. ARC-IM consists of one

implantable pulse generator and an electrode placed near the

Spinal cord is placed. The company has the 2022 ARC-IM neurostimulator

first used in humans.

ONWARD’s headquarters are located in Eindhoven, Netherlands. The

The company has a science and technology center in Lausanne,

Switzerland, and a growing presence in the US in Boston, Massachusetts. ONWARD

connects an academic partnership with.NeuroRestore, a collaboration

between the Swiss Federal Institute of Technology in Lausanne (EPFL) and the

Lausanne University Hospital (CHUV). More information about the company

can be found at ONWD.com (https://www.onwd.com/). The financial calendar 2023

can be found at IR.ONWD.com (https://ir.onwd.com/).

For corporate inquiries:

[email protected] (mailto:[email protected])

For media inquiries:

MC Services AG

USA: Laurie Doyle, P: +1 339 832 0752

Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0

[email protected] (mailto:[email protected])

For investor inquiries:

[email protected] (mailto:[email protected])

Disclaimer

Certain statements, beliefs and opinions contained in this press release are

future-oriented and reflect the current expectations and forecasts

company or the board of directors of the company with regard to future

events reflected. It is in the nature of things that future-oriented

Statements involve a number of risks, uncertainties and assumptions

could cause actual results or events to differ materially

differ from those expressed or expressed in the forward-looking statements

be implied. These risks, uncertainties and assumptions could

Outcome and financial impact of the plans described herein and

negatively influence events. A variety of factors including,

but not limited to, changes in demand, competition and

Technology, can cause actual events, achievements

or results deviate significantly from the expected development.

Forward-looking statements in this press release relate to past

Any reference to trends or activities should not be understood as a guarantee that

these trends or activities will continue in the future. Therefore rejects this

Company expressly disclaims any obligation to provide updates or

Corrections to the forward-looking statements contained in this press release

to publish statements if the expectations or the events,

Conditions, assumptions or circumstances on which these forward-looking

Based on statements, change. Neither the company nor its advisors or

representatives, nor one of its subsidiaries, nor the executive officers

or employees of such persons guarantee that the assumptions made by such persons

the forward-looking statements are based on, are error-free

you assume responsibility for the future accuracy of this

any forward-looking statements or actual statements contained in this press release

Occurrence of the forecast developments. You shouldn’t be in

Inappropriately rely on forward-looking statements, which are intended only for the purpose

as of the date of this press release.

°

ttn-28